Subjects -> MEDICAL SCIENCES (Total: 8821 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (224 journals)
    - ANAESTHESIOLOGY (121 journals)
    - CARDIOVASCULAR DISEASES (350 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (292 journals)
    - DERMATOLOGY AND VENEREOLOGY (167 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (127 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (44 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (192 journals)
    - GERONTOLOGY AND GERIATRICS (143 journals)
    - HEMATOLOGY (159 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (180 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (100 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2458 journals)
    - NURSES AND NURSING (372 journals)
    - OBSTETRICS AND GYNECOLOGY (211 journals)
    - ONCOLOGY (393 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (143 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (172 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (277 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (161 journals)
    - PSYCHIATRY AND NEUROLOGY (848 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (195 journals)
    - RESPIRATORY DISEASES (108 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (83 journals)
    - SURGERY (412 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)

UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)                     

Showing 1 - 159 of 159 Journals sorted alphabetically
Acta Urológica Portuguesa     Open Access   (Followers: 1)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 1)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 11)
Advances in Urology     Open Access   (Followers: 13)
African Journal of Nephrology     Open Access  
African Journal of Urology     Open Access   (Followers: 7)
AJP Renal Physiology     Hybrid Journal   (Followers: 8)
Aktuelle Urologie     Hybrid Journal   (Followers: 4)
American Journal of Kidney Diseases     Hybrid Journal   (Followers: 42)
American Journal of Men's Health     Open Access   (Followers: 9)
American Journal of Nephrology     Full-text available via subscription   (Followers: 38)
Andrologia     Hybrid Journal   (Followers: 2)
Andrology     Hybrid Journal   (Followers: 4)
Andrology & Gynecology : Current Research     Hybrid Journal   (Followers: 4)
Andrology and Genital Surgery     Open Access   (Followers: 7)
Andrology-Open Access     Open Access  
Annales d'Urologie     Full-text available via subscription  
Arab Journal of Nephrology and Transplantation     Open Access   (Followers: 1)
Arab Journal of Urology     Open Access   (Followers: 7)
Archives of Clinical Nephrology     Open Access   (Followers: 2)
Archivio Italiano di Urologia e Andrologia     Open Access   (Followers: 1)
Archivos Españoles de Urología     Open Access  
Asian Journal of Andrology     Open Access   (Followers: 1)
Asian Journal of Urology     Open Access   (Followers: 3)
Bangladesh Journal of Urology     Open Access   (Followers: 5)
BANTAO Journal     Open Access  
Basic and Clinical Andrology     Open Access  
BJU International     Hybrid Journal   (Followers: 34)
BJUI Compass     Open Access   (Followers: 2)
BMC Nephrology     Open Access   (Followers: 11)
BMC Urology     Open Access   (Followers: 14)
Canadian Journal of Kidney Health and Disease     Open Access   (Followers: 8)
Canadian Urological Association Journal     Open Access   (Followers: 2)
Cancer Urology     Open Access   (Followers: 2)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Case Reports in Nephrology     Open Access   (Followers: 5)
Case Reports in Nephrology and Dialysis     Open Access   (Followers: 9)
Case Reports in Urology     Open Access   (Followers: 12)
Clinical and Experimental Nephrology     Hybrid Journal   (Followers: 4)
Clinical Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 22)
Clinical Kidney Journal     Open Access   (Followers: 4)
Clinical Medicine Insights : Urology     Open Access   (Followers: 3)
Clinical Nephrology     Full-text available via subscription   (Followers: 8)
Clinical Nephrology and Urology Science     Open Access   (Followers: 6)
Clinical Queries: Nephrology     Hybrid Journal   (Followers: 1)
Cuadernos de Cirugía     Open Access   (Followers: 3)
Current Opinion in Nephrology & Hypertension     Hybrid Journal   (Followers: 10)
Current Opinion in Urology     Hybrid Journal   (Followers: 12)
Current Urology     Open Access   (Followers: 10)
Current Urology Reports     Hybrid Journal   (Followers: 5)
Der Nephrologe     Hybrid Journal  
Der Urologe     Hybrid Journal   (Followers: 1)
Diabetic Nephropathy     Open Access   (Followers: 1)
EMC - Urología     Full-text available via subscription  
Enfermería Nefrológica     Open Access   (Followers: 1)
European Urology     Full-text available via subscription   (Followers: 33)
European Urology Focus     Hybrid Journal   (Followers: 5)
European Urology Oncology     Hybrid Journal   (Followers: 1)
European Urology Open Science     Open Access   (Followers: 10)
Forum Nefrologiczne     Full-text available via subscription  
Geriatric Nephrology and Urology     Hybrid Journal   (Followers: 7)
Giornale di Clinica Nefrologica e Dialisi     Open Access  
Herald Urology     Open Access   (Followers: 2)
Hong Kong Journal of Nephrology     Open Access   (Followers: 3)
Human Andrology     Partially Free   (Followers: 2)
IJU Case Reports     Open Access  
Indian Journal of Nephrology     Open Access   (Followers: 2)
Indian Journal of Urology     Open Access   (Followers: 5)
International Brazilian Journal of Urology     Open Access   (Followers: 5)
International Journal of Nephrology     Open Access   (Followers: 2)
International Journal of Nephrology and Renovascular Disease     Open Access   (Followers: 2)
International Journal of Urology     Hybrid Journal   (Followers: 12)
International Urology and Nephrology     Hybrid Journal   (Followers: 7)
Jornal Brasileiro de Nefrologia     Open Access  
Journal für Urologie und Urogynäkologie/Österreich     Hybrid Journal  
Journal of Clinical Nephrology     Open Access   (Followers: 2)
Journal of Clinical Urology     Hybrid Journal   (Followers: 14)
Journal of Endoluminal Endourology     Open Access  
Journal of Endourology     Hybrid Journal   (Followers: 2)
Journal of Endourology Case Reports     Hybrid Journal  
Journal of Genital System & Disorders     Hybrid Journal   (Followers: 3)
Journal of Integrative Nephrology and Andrology     Open Access   (Followers: 2)
Journal of Kidney Cancer and VHL     Open Access  
Journal of Lower Genital Tract Disease     Hybrid Journal  
Journal of Nephrology     Hybrid Journal   (Followers: 4)
Journal of Nephrology Research     Open Access   (Followers: 3)
Journal of Pediatric Nephrology     Open Access   (Followers: 5)
Journal of Renal Care     Hybrid Journal   (Followers: 8)
Journal of Renal Nursing     Full-text available via subscription   (Followers: 12)
Journal of Renal Nutrition     Hybrid Journal   (Followers: 28)
Journal of Renal Nutrition and Metabolism     Open Access   (Followers: 1)
Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 31)
Journal of The Egyptian Society of Nephrology and Transplantation     Open Access  
Journal of Translational Neurosciences     Open Access  
Journal of Urology     Full-text available via subscription   (Followers: 46)
Journal of Urology & Nephrology     Open Access   (Followers: 2)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney Diseases     Open Access   (Followers: 3)
Kidney International     Hybrid Journal   (Followers: 46)
Kidney International Reports     Open Access   (Followers: 3)
Kidney Medicine     Open Access  
Kidney Research Journal     Open Access   (Followers: 6)
Kidneys (Počki)     Open Access   (Followers: 1)
Nature Reviews Nephrology     Full-text available via subscription   (Followers: 22)
Nature Reviews Urology     Full-text available via subscription   (Followers: 13)
Nefrología (English Edition)     Open Access  
Nefrología (Madrid)     Open Access  
Nephro-Urology Monthly     Open Access   (Followers: 1)
Nephrology     Hybrid Journal   (Followers: 13)
Nephrology Dialysis Transplantation     Hybrid Journal   (Followers: 27)
Nephron     Hybrid Journal   (Followers: 4)
Nephron Clinical Practice     Full-text available via subscription   (Followers: 4)
Nephron Experimental Nephrology     Full-text available via subscription   (Followers: 4)
Nephron Extra     Open Access   (Followers: 1)
Nephron Physiology     Full-text available via subscription   (Followers: 4)
Neurourology and Urodynamics     Hybrid Journal   (Followers: 1)
OA Nephrology     Open Access   (Followers: 2)
Open Access Journal of Urology     Open Access   (Followers: 6)
Open Journal of Nephrology     Open Access   (Followers: 5)
Open Journal of Urology     Open Access   (Followers: 6)
Open Urology & Nephrology Journal     Open Access  
Pediatric Urology Case Reports     Open Access   (Followers: 7)
Portuguese Journal of Nephrology & Hypertension     Open Access   (Followers: 1)
Progrès en Urologie     Full-text available via subscription  
Progrès en Urologie - FMC     Full-text available via subscription  
Prostate Cancer and Prostatic Diseases     Hybrid Journal   (Followers: 6)
Renal Failure     Open Access   (Followers: 12)
Renal Replacement Therapy     Open Access   (Followers: 4)
Research and Reports in Urology     Open Access   (Followers: 4)
Revista de Nefrología, Diálisis y Trasplante     Open Access   (Followers: 1)
Revista Mexicana de Urología     Open Access   (Followers: 1)
Revista Urologia Colombiana     Open Access  
Saudi Journal of Kidney Diseases and Transplantation     Open Access   (Followers: 2)
Scandinavian Journal of Urology     Hybrid Journal   (Followers: 7)
Seminars in Nephrology     Hybrid Journal   (Followers: 11)
The Prostate     Hybrid Journal   (Followers: 8)
Therapeutic Advances in Urology     Open Access   (Followers: 4)
Trends in Urology & Men's Health     Partially Free   (Followers: 1)
Ukrainian Journal of Nephrology and Dialysis     Open Access   (Followers: 1)
Uro-News     Hybrid Journal   (Followers: 1)
Urolithiasis     Hybrid Journal   (Followers: 2)
Urologia Internationalis     Full-text available via subscription   (Followers: 2)
Urologia Journal     Hybrid Journal  
Urologic Clinics of North America     Full-text available via subscription   (Followers: 4)
Urologic Nursing     Full-text available via subscription   (Followers: 4)
Urologic Radiology     Hybrid Journal  
Urological Science     Open Access  
Urologicheskie Vedomosti     Open Access  
Urologie in der Praxis     Hybrid Journal  
Urologie Scan     Hybrid Journal  
Urology     Hybrid Journal   (Followers: 33)
Urology Annals     Open Access   (Followers: 4)
Urology Case Reports     Open Access   (Followers: 3)
Urology Practice     Full-text available via subscription   (Followers: 2)
Urology Times     Free   (Followers: 3)
Urology Video Journal     Open Access   (Followers: 1)
World Journal of Nephrology and Urology     Open Access   (Followers: 15)
World Journal of Urology     Hybrid Journal   (Followers: 11)

           

Similar Journals
Journal Cover
Nephrology Dialysis Transplantation
Journal Prestige (SJR): 2.142
Citation Impact (citeScore): 4
Number of Followers: 27  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0931-0509 - ISSN (Online) 1460-2385
Published by Oxford University Press Homepage  [415 journals]
  • Effects of calcitriol and paricalcitol on renal fibrosis in CKD
    • Authors: Martínez-Arias L; Panizo S, Alonso-Montes C, et al.
      Pages: 793 - 803
      Abstract: BackgroundIn chronic kidney disease, the activation of the renin–angiotensin–aldosterone system (RAAS) and renal inflammation stimulates renal fibrosis and the progression to end-stage renal disease. The low levels of vitamin D receptor (VDR) and its activators (VDRAs) contribute to worsen secondary hyperparathyroidism and renal fibrosis. MethodsThe 7/8 nephrectomy model of experimental chronic renal failure (CRF) was used to examine the anti-fibrotic effects of treatment with two VDRAs, paricalcitol and calcitriol, at equivalent doses (3/1 dose ratio) during 4 weeks.ResultsCRF increased the activation of the RAAS, renal inflammation and interstitial fibrosis. Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the RAAS through renal changes in renin, angiotensin receptor 1 (ATR1) and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leucocytes (CD45), a desintegrin and metaloproteinase mRNA, transforming growth factor beta mRNA and protein, and maintaining E-cadherin mRNA levels. Calcitriol showed similar trends without significant changes in most of these biomarkers.ConclusionsParicalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the RAAS, inflammation and epithelial/mesenchymal transition.
      PubDate: Fri, 08 Jan 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa373
      Issue No: Vol. 36, No. 5 (2021)
       
  • Does kidney transplantation with a standard or expanded criteria donor
           improve patient survival' Results from a Belgian cohort
    • Authors: Hellemans R; Kramer A, De Meester J, et al.
      Pages: 918 - 926
      Abstract: BackgroundChanges in recipient and donor factors have reopened the question of survival benefits of kidney transplantation versus dialysis.MethodsWe analysed survival among 3808 adult Belgian patients waitlisted for a first deceased donor kidney transplant from 2000 to 2012. The primary outcome was mortality during the median waiting time plus 3 years of follow-up after transplantation or with continued dialysis. Outcomes were analysed separately for standard criteria donor (SCD) and expanded criteria donor (ECD) kidney transplants. We adjusted survival analyses for recipient age (20–44, 45–64 and ≥65 years), sex and diabetes as the primary renal disease.ResultsAmong patients ≥65 years of age, only SCD transplantation provided a significant survival benefit compared with dialysis, with a mortality of 16.3% [95% confidence interval (CI) 13.2–19.9] with SCD transplantation, 20.5% (95% CI 16.1–24.6) with ECD transplantation and 24.6% (95% CI 19.4–29.5) with continued dialysis. Relative mortality risk was increased in the first months after transplantation compared with dialysis, with equivalent risk levels reached earlier with SCD than ECD transplantation in all age groups.ConclusionsThe results of this study suggest that older patients might gain a survival benefit with SCD transplantation versus dialysis, but any survival benefit with ECD transplantation versus dialysis may be small.
      PubDate: Fri, 26 Feb 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfab024
      Issue No: Vol. 36, No. 5 (2021)
       
  • Pilot study of reloxaliase in patients with severe enteric hyperoxaluria
           and hyperoxalemia
    • Authors: Pfau A; Grujic D, Keddis M, et al.
      Pages: 945 - 948
      Abstract: Enteric hyperoxaluria (EH) is a serious condition that affects ∼250 000 people in the USA and can lead to recurrent kidney stones, oxalate nephropathy and chronic kidney disease (CKD) with a risk of kidney failure requiring chronic dialysis [1–3]. It is characterized by excessive urine oxalate (UOx) excretion ≥40 mg/24 h that is necessitated by increased intestinal oxalate absorption [4] as a consequence of gastrointestinal (GI) conditions associated with fat malabsorption [5]. When estimated glomerular filtration rate (eGFR) declines, plasma oxalate (POx) concentrations rise reflecting systemic oxalate load [6]. In severe courses of disease indicated by markedly increased POx concentrations, oxalate may deposit in various tissues throughout the body, a life-threatening condition called systemic oxalosis [7, 8]. However, to date, therapeutic options are limited with a focus on dietary modifications [4].
      PubDate: Fri, 08 Jan 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa379
      Issue No: Vol. 36, No. 5 (2021)
       
  • Subfertility and early menopause in women with glomerular disease
    • Authors: Reynolds M; Poulton C, Blazek L, et al.
      Pages: 948 - 950
      Abstract: Subfertility, an inability to achieve desired conception for an extended period, affects up to one in six couples and leads to considerable psychological distress [1]. Due to an altered hypothalamic–pituitary–ovarian axis, women with advanced chronic kidney disease (CKD) are more likely to experience menstrual irregularities, subfertility and early menopause [2–6]. Autoimmune diseases, including systemic lupus erythematosus and antiphospholipid antibody syndrome, are associated with subfertility related to autoantibodies, autoimmune oophoritis and medical treatment [7, 8].
      PubDate: Thu, 04 Feb 2021 00:00:00 GMT
      DOI: 10.1093/ndt/gfab005
      Issue No: Vol. 36, No. 5 (2021)
       
  • Controlling pain in dialysis care: a choice among undesirable options
    • Authors: Cowan A; Garg A.
      Pages: 749 - 751
      Abstract: Chronic pain and analgesic medication use are common among patients who receive ongoing dialysis [1–3]. According to recommendations in the World Health Organization pain ladder, opioids are generally avoided until nonopioid medications are proven ineffective [4]. Regularly scheduled acetaminophen is used, however, many patients report little benefit. In the dialysis population, many physicians recommend ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs), reassured that once a person’s kidneys fail the risk of nephrotoxicity is far less relevant.
      PubDate: Fri, 06 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa256
      Issue No: Vol. 36, No. 5 (2020)
       
  • A plea for renin–angiotensin system blockers as first-line treatment in
           cases of severe acute hypertension
    • Authors: Rubin S; Boulestreau R, Gosse P, et al.
      Pages: 752 - 753
      Abstract: The management of hypertension as a chronic disease is now well codified. Over the last 10 years, blockers of the renin–angiotensin system (RAS) have become first-line drugs, often combined with diuretics or calcium channel blockers, particularly in the population of patients with chronic kidney disease [1]. The management of acute and severe hypertension is much less clear-cut. Expert recommendations in this area are based on very low levels of evidence. However, there is a relative consensus on treatment based on intravenous (IV) infusion of antihypertensive therapy in the first days. Labetalol, nicardipine and urapidil are the most frequently used drugs in this setting. The aim is to progressively reduce blood pressure (BP) to 140/90 mmHg in the first 2 or 3 days. We believe that these recommendations result in underuse of RAS blockers [2].
      PubDate: Fri, 25 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa313
      Issue No: Vol. 36, No. 5 (2020)
       
  • New evidence shows it is time to stop unnecessary use of antibiotics in
           kidney transplant recipients with asymptomatic bacteriuria
    • Authors: Coussement J; Kamar N, Abramowicz D.
      Pages: 754 - 756
      Abstract: In 2014, we published an article in Nephrology Dialysis Transplantation questioning the usefulness of screening for and treating asymptomatic bacteriuria in kidney transplant recipients [1]. At that time, it was common practice in our institutions and in many others to routinely screen for asymptomatic bacteriuria after kidney transplantation. A urine culture was therefore systematically ordered at each post-transplant follow-up visit. Patients found to have bacteriuria were regularly prescribed antibiotics, even if they had no symptoms of urinary tract infection. A survey in 2017 confirmed that this practice was still common in European transplant centers [2].
      PubDate: Sun, 27 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa341
      Issue No: Vol. 36, No. 5 (2020)
       
  • Sodium zirconium cyclosilicate for hyperkalemia: a collateral
           acid–base benefit'
    • Authors: Wesson D.
      Pages: 756 - 760
      Abstract: Clinicians recognize the toxicity of hyperkalemia, and its need for treatment, due to compromised kidney potassium (K+) excretory capacity that accompanies a progressive loss of glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD) [1]. Less recognized is the growing evidence supporting the toxicity of acid (hydrogen, H+) accumulation that also occurs with progressive GFR decline. Normally functioning kidneys can balance metabolic H+ production with excretion to avoid ongoing H+ accumulation. Patients with CKD and progressive GFR decline are less able to fully excrete metabolically produced H+, causing progressive H+ accumulation [2]. Those with CKD and H+ accumulation that is enough to reduce serum bicarbonate concentration ([HCO3−]), that is, have metabolic acidosis, suffer harm to bones [3], muscles [4] and kidneys [5], and premature mortality [6]. Treatment of CKD-related metabolic acidosis to increase serum [HCO3−] with oral sodium bicarbonate (NaHCO3) reduces harm to each of these organ systems [7–9] and reduces mortality [10]. In addition, those with CKD and H+ accumulation that is not enough to reduce serum [HCO3−] [11], called ‘eubicarbonatemic acidosis’ [12], ‘preclinical acidosis’ [13] or ‘subclinical acidosis’ [14], also suffer kidney injury [15], and its treatment with oral NaHCO3 reduces kidney injury [15] and slows CKD progression [16]. These data suggest the need for clinicians to treat harmful H+ accumulation as well as hyperkalemia in CKD.
      PubDate: Thu, 12 Nov 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa241
      Issue No: Vol. 36, No. 5 (2020)
       
  • Dickkopf 3—a novel biomarker of the ‘kidney injury
           continuum’
    • Authors: Schunk S; Speer T, Petrakis I, et al.
      Pages: 761 - 767
      Abstract: Chronic kidney disease (CKD) is a global public health problem accompanied by substantial comorbidities and reduced life expectancy. In this respect, progressive CKD leading to uraemia can be seen as a systemic disease with a critical impact on virtually all organ systems. Therefore, it is of particular importance to identify patients with ongoing CKD progression, which is challenging, because the individual course of CKD is difficult to predict. Patterns of progression in CKD patients include linear and non-linear trajectories of GFR loss, but kidney function can also remain stable for years. Moreover, a substantial GFR decline may occur in the absence of higher-grade albuminuria (non-proteinuric CKD), rendering the measurement of albuminuria less reliable for progression prediction in such individuals. In the present review, we focus on the recently identified glycoprotein Dickkopf-3 (DKK3) as a stress-induced, renal tubular epithelial cell-derived, pro-fibrotic molecule. In experimental CKD models, DKK3 promoted renal tubulointerstitial fibrosis through modulation of the canonical Wnt/β-catenin signalling pathway. In clinical studies, increased urinary DKK3 levels identified patients at high risk for short-term CKD progression, regardless of the cause of kidney disease, baseline kidney function and albuminuria. Moreover, increased urinary DKK3 levels are associated with a high risk for acute kidney injury and the subsequent loss of kidney function after cardiac surgery. These findings highlight DKK3 as a mediator of renal tubular cell damage in kidney injury and short-term progression of kidney disease, with potential therapeutic implications.
      PubDate: Wed, 05 Feb 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa003
      Issue No: Vol. 36, No. 5 (2020)
       
  • The evolution of the therapeutic approach to membranous nephropathy
    • Authors: Ponticelli C; Patrizia P, Del Vecchio L, et al.
      Pages: 768 - 773
      Abstract: Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome (NS) in adults. In untreated patients, the outcome is variable, with one-third of the patients entering remission while the remaining ones show persisting proteinuria or progression to end-stage renal disease. Randomized clinical trials reported the efficacy of a 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month. The potential side effects of this regimen were limited by the fact that the use of glucocorticoids and alkylating agent did not exceed 3 months each. Two randomized trials with follow-ups (FU) up to 10 years provided assurance about the long-term efficacy and safety of this cyclical therapy. Calcineurin inhibitors have also been used successfully. However, in most responders, NS relapsed after the drug was withdrawn. Conflicting results have been reported with mycophenolate salts and adrenocorticotropic hormone. Observational studies reported good results with rituximab (RTX). Two controlled trials demonstrated the superiority of RTX over antiproteinuric therapy alone and cyclosporine. However, the FUs were relatively short and no randomized trial has been published against cyclical therapy. The available results, together with the discovery that most patients with MN have circulating antibodies against the phospholipase A2 receptor 1, support the use of cytotoxic drugs or RTX in MN. It is difficult to choose between these two different treatments. RTX is easier to use, but the FUs of the available studies are short, thus doubts remain about the long-term risk of relapses and the safety of repeated administrations of RTX.
      PubDate: Tue, 24 Mar 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa014
      Issue No: Vol. 36, No. 5 (2020)
       
  • Mass spectrometry-based screening identifies circulating
           immunoglobulinA–α1-microglobulin complex as potential biomarker in
           immunoglobulin A nephropathy
    • Authors: Xu B; Zhu L, Wang Q, et al.
      Pages: 782 - 792
      Abstract: BackgroundImmunoglobulin A nephropathy (IgAN) is characterized by predominant IgA deposition in the glomerular mesangium. Previous studies have proved that renal-deposited IgA in IgAN came from circulating IgA1-containing complexes (CICs). MethodsTo explore the composition of CICs in IgAN, we isolated CICs from IgAN patients and healthy controls and then quantitatively analyzed them by mass spectrometry. Meanwhile, the isolated CICs were used to treat human mesangial cells to monitor mesangial cell injury. Using the protein content and injury effects, the key constituent in CICs was identified. Then the circulating levels of identified key constituent–IgA complex were detected in an independent population by an in-house-developed enzyme-linked immunosorbent assay.ResultsBy comparing the proteins of CICs between IgAN patients and controls, we found that 14 proteins showed significantly different levels. Among them, α1-microglobulin content in CICs was associated with not only in vitro mesangial cell proliferation and monocyte chemoattractant protein 1 secretion, but also in vivo estimated glomerular filtration rate (eGFR) levels and tubulointerstitial lesions in IgAN patients. Moreover, we found α1-microglobulin was prone to bind aberrant glycosylated IgA1. Additionally, elevated circulating IgA-α1-microglobulin complex levels were detected in an independent IgAN population and IgA-α1-microglobulin complex levels were correlated with hypertension, eGFR levels and Oxford T- scores in these IgAN patients.ConclusionsOur results suggest that the IgA-α1-microglobulin complex is an important constituent in CICs and that circulating IgA-α1-microglobulin complex detection might serve as a potential noninvasive biomarker detection method for IgAN.
      PubDate: Tue, 22 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa352
      Issue No: Vol. 36, No. 5 (2020)
       
  • Renal SPECT/CT with 99mTc–dimercaptosuccinic acid is a non-invasive
           predictive marker for the development of interstitial fibrosis in a rat
           model of renal insufficiency
    • Authors: Bobot M; Hache G, Moyon A, et al.
      Pages: 804 - 810
      Abstract: BackgroundChronic kidney disease (CKD) increases cardiovascular risk and mortality. Renal fibrosis plays a major role in the progression of CKD but, to date, histology remains the gold standard to assess fibrosis. Non-invasive techniques are needed to assess renal parenchymal impairment and to perform the longitudinal evaluation of renal structure. Thus we evaluated renal isotopic imaging by single-photon emission computed tomography/computed tomography (SPECT/CT) with technetium-99m (99mTc)–dimercaptosuccinic acid (DMSA) to monitor renal impairment during renal insufficiency in rats.MethodsRenal insufficiency was induced by an adenine-rich diet (ARD) at 0.25 and 0.5% for 28 days. Renal dysfunction was evaluated by assaying biochemical markers and renal histology. Renal parenchymal impairment was assessed by SPECT/CT isotopic imaging with 99mTc-DMSA on Days 0, 7, 14, 21, 28, 35 and 49.ResultsCompared with controls, ARD rats developed renal dysfunction characterized by increased serum creatinine and blood urea nitrogen, fibrosis and tubulointerstitial damage in the kidneys, with a dose-dependent effect of the adenine concentration. 99mTc-DMSA SPECT-CT imaging showed a significant decrease in renal uptake over time in 0.25 and 0.5% ARD rats compared with control rats (P = 0.011 and P = 0.0004, respectively). 99mTc-DMSA uptake on Day 28 was significantly inversely correlated with Sirius red staining evaluated on Day 49 (r = 0.89, P < 0.0001, R2 = 0.67).Conclusions99mTc-DMSA renal scintigraphy allows a longitudinal follow-up of risk of renal fibrosis in rats. We found that the reduction of renal parenchyma in ARD rats is inversely proportional to newly formed fibrous tissue in the kidney. Our results suggest that 99mTc-DMSA renal scintigraphy may be a useful non-invasive prognostic marker of the development of renal fibrosis in animals and should be tested in humans.
      PubDate: Wed, 23 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa374
      Issue No: Vol. 36, No. 5 (2020)
       
  • Non-medical barriers reported by nephrologists when providing renal
           replacement therapy or comprehensive conservative management to end-stage
           kidney disease patients: a systematic review
    • Authors: de Jong R; Stel V, Heaf J, et al.
      Pages: 848 - 862
      Abstract: BackgroundLarge international differences exist in access to renal replacement therapy (RRT) modalities and comprehensive conservative management (CCM) for patients with end-stage kidney disease (ESKD), suggesting that some patients are not receiving the most appropriate treatment. Previous studies mainly focused on barriers reported by patients or medical barriers (e.g. comorbidities) reported by nephrologists. An overview of the non-medical barriers reported by nephrologists when providing the most appropriate form of RRT (other than conventional in-centre haemodialysis) or CCM is lacking. MethodsWe searched in EMBASE and PubMed for original articles with a cross-sectional design (surveys, interviews or focus groups) published between January 2010 and September 2018. We included studies in which nephrologists reported barriers when providing RRT or CCM to adult patients with ESKD. We used the barriers and facilitators survey by Peters et al. [Ruimte Voor Verandering' Knelpunten en Mogelijkheden Voor Verbeteringen in de Patiëntenzorg. Nijmegen: Afdeling Kwaliteit van zorg (WOK), 2003] as preliminary framework to create our own model and performed meta-ethnographic analysis of non-medical barriers in text, tables and figures. ResultsOf the 5973 articles screened, 16 articles were included using surveys (n = 10), interviews (n = 5) and focus groups (n = 1). We categorized the barriers into three levels: patient level (e.g. attitude, role perception, motivation, knowledge and socio-cultural background), level of the healthcare professional (e.g. fears and concerns, working style, communication skills) and level of the healthcare system (e.g. financial barriers, supportive staff and practice organization).ConclusionsOur systematic review has identified a number of modifiable, non-medical barriers that could be targeted by, for example, education and optimizing financing structure to improve access to RRT modalities and CCM.
      PubDate: Fri, 03 Jan 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfz271
      Issue No: Vol. 36, No. 5 (2020)
       
  • Kidney function and symptom development over time in elderly patients with
           advanced chronic kidney disease: results of the EQUAL cohort study
    • Authors: Janmaat C; van Diepen M, Meuleman Y, et al.
      Pages: 862 - 870
      Abstract: BackgroundInitiation of renal replacement therapy often results from a combination of kidney function deterioration and symptoms related to chronic kidney disease (CKD) progression. We investigated the association between kidney function decline and symptom development in patients with advanced CKD.MethodsIn the European Quality study on treatment in advanced CKD (EQUAL study), a European prospective cohort study, patients with advanced CKD aged ≥65 years and a kidney function that dropped <20 mL/min/1.73 m2 were followed for 1 year. Linear mixed-effects models were used to assess the association between kidney function decline and symptom development. The sum score for symptom number ranged from 0 to 33 and for overall symptom severity from 0 to 165, using the Dialysis Symptom Index.ResultsAt least one kidney function estimate with symptom number or overall symptom severity was available for 1109 and 1019 patients, respectively. The mean (95% confidence interval) annual kidney function decline was 1.70 (1.32; 2.08) mL/min/1.73 m2. The mean overall increase in symptom number and severity was 0.73 (0.28; 1.19) and 2.93 (1.34; 4.52) per year, respectively. A cross-sectional association between the level of kidney function and symptoms was lacking. Furthermore, kidney function at cohort entry was not associated with symptom development. However, each mL/min/1.73 m2 of annual kidney function decline was associated with an extra annual increase of 0.23 (0.07; 0.39) in the number of symptoms and 0.87 (0.35; 1.40) in overall symptom severity.ConclusionsA faster kidney function decline was associated with a steeper increase in both symptom number and severity. Considering the modest association, our results seem to suggest that repeated thorough assessment of symptom development during outpatient clinic visits, in addition to the monitoring of kidney function decline, is important for clinical decision-making.
      PubDate: Tue, 14 Jan 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfz277
      Issue No: Vol. 36, No. 5 (2020)
       
  • Sodium zirconium cyclosilicate increases serum bicarbonate concentrations
           among patients with hyperkalaemia: exploratory analyses from three
           randomized, multi-dose, placebo-controlled trials
    • Authors: Roger S; Spinowitz B, Lerma E, et al.
      Pages: 871 - 883
      Abstract: BackgroundSodium zirconium cyclosilicate (SZC) binds potassium and ammonium in the gastrointestinal tract. In addition to serum potassium reduction, Phase 2 trial data have shown increased serum bicarbonate with SZC, which may be clinically beneficial because maintaining serum bicarbonate ≥22 mmol/L preserves kidney function. This exploratory analysis examined serum bicarbonate and urea, and urine pH data from three SZC randomized, placebo-controlled Phase 3 studies among patients with hyperkalaemia [ZS-003 (n = 753), HARMONIZE (n = 258) and HARMONIZE-Global (n = 267)].MethodsIn all studies, patients received ≤10 g SZC 3 times daily (TID) for 48 h to correct hyperkalaemia, followed by randomization to maintenance therapy with SZC once daily (QD) versus placebo for ≤29 days among those achieving normokalaemia.ResultsSignificant dose-dependent mean serum bicarbonate increases from baseline of 0.3 to 1.5 mmol/L occurred within 48 h of SZC TID in ZS-003 (all P < 0.05), which occurred regardless of chronic kidney disease (CKD) stage. Similar acute increases in HARMONIZE and HARMONIZE-Global were maintained over 29 days. With highest SZC maintenance doses, patient proportions with serum bicarbonate <22 mmol/L fell from 39.4% at baseline to 4.9% at 29 days (P = 0.005) in HARMONIZE and from 87.9% to 70.1%, (P = 0.006) in HARMONIZE-Global. Path analyses demonstrated that serum urea decreases (but not serum potassium or urine pH changes) were associated with SZC effects on serum bicarbonate.ConclusionsSZC increased serum bicarbonate concentrations and reduced patient proportions with serum bicarbonate <22 mmol/L, likely due to SZC-binding of gastrointestinal ammonium. These SZC-induced serum bicarbonate increases occurred regardless of CKD stage and were sustained during ongoing maintenance therapy.
      PubDate: Fri, 26 Jun 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa158
      Issue No: Vol. 36, No. 5 (2020)
       
  • Apixaban in patients on haemodialysis: a single-dose pharmacokinetics
           study
    • Authors: Van den Bosch I; Bouillon T, Verhamme P, et al.
      Pages: 884 - 889
      Abstract: BackgroundApixaban, a direct oral anticoagulant inhibiting factor Xa, has been proven to reduce the risk of atrial fibrillation-related stroke and thromboembolism in patients with mild to moderate renal insufficiency. Patients on renal replacement therapy, however, were excluded from randomized controlled trials. Therefore, uncertainty remains concerning benefits, dosing and timing of intake in haemodialysis population.MethodsWe conducted a Phase II pharmacokinetics study in which 24 patients on maintenance haemodialysis were given a single dose (2.5 mg or 5 mg) of apixaban, either 30 min before or immediately after dialysis on the mid-week dialysis day.ResultsApixaban 5 mg resulted in higher area under the curve (AUC0–48) in comparison with 2.5 mg, although significance could only be reached for dosing pre-dialysis (2.5 mg versus 5 mg, P = 0.008). In line, peak concentrations (Cmax) after dosing pre-dialysis were significantly higher in the 5 mg than in the 2.5 mg groups (P = 0.02). In addition, dialysis resulted in significant reduction of drug exposure. AUC0–48 pre-dialysis were on average 48% (2.5 mg) and 26% (5 mg) lower than the AUC0–48 post-dialysis, in line with Cmax. As a result, a dose of 2.5 mg post-dialysis and a dose of 5 mg pre-dialysis resulted in similar AUC0–48. In contrast, significant differences were found between the 5 mg group post-dialysis and the 2.5 mg group pre-dialysis (P = 0.02).ConclusionsOur data suggest that exposure to apixaban in patients on maintenance haemodialysis is dependent not only on drug dose but also on timing of intake relative to the haemodialysis procedure.
      PubDate: Tue, 22 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa351
      Issue No: Vol. 36, No. 5 (2020)
       
  • Patient-reported outcome measures for life participation in peritoneal
           dialysis: a systematic review
    • Authors: Manera K; Ju A, Baumgart A, et al.
      Pages: 890 - 901
      Abstract: BackgroundPatients receiving peritoneal dialysis (PD) endure an ongoing regimen of daily fluid exchanges and are at risk of potentially life-threatening complications and debilitating symptoms that can limit their ability to participate in life activities. The aim of the study was to identify the characteristics, content and psychometric properties of measures for life participation used in research in PD.MethodsWe searched MEDLINE, Embase, PsychInfo, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane Central Register of Controlled Trials from inception to May 2020 for all studies that reported life participation in patients on PD. The characteristics, dimensions of life participation and psychometric properties of these measures were extracted and analyzed.ResultsOf the 301 studies included, 17 (6%) were randomized studies and 284 (94%) were nonrandomized studies. Forty-two different measures were used to assess life participation. Of these, 23 (55%) were used in only one study. Fifteen (36%) measures were specifically designed to assess life participation, while 27 (64%) measures assessed broader constructs, such as quality of life, but included questions on life participation. The 36-Item Short Form Health Survey and Kidney Disease Quality of Life Short Form were the most frequently used measures [122 (41%) and 86 (29%) studies, respectively]. Eight (19%) measures had validation data to support their use in patients on PD.ConclusionsThe many measures currently used to assess life participation in patients receiving PD vary in their characteristics, content and validation. Further work to pilot and validate potential measures is required to establish a core patient-reported outcome measure to assess life participation in patients receiving PD.
      PubDate: Sat, 26 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa244
      Issue No: Vol. 36, No. 5 (2020)
       
  • Impact of dialysis modality on major adverse cardiovascular events and
           all-cause mortality: a national population-based study
    • Authors: Hu P; Chen Y, Chen T, et al.
      Pages: 901 - 908
      Abstract: BackgroundOnly few studies with inconsistent results comparing the relative risk of cardiac mortality between peritoneal dialysis (PD) and hemodialysis (HD). Switches between renal replacement therapy (RRT) modalities render objective assessment of survival benefits a greater challenge.MethodsData were retrieved from Taiwan’s National Health Insurance Database from 1 January 2006 to 31 December 2015. We included 13 662 and 41 047 long-term dialysis patients in a propensity score matching study design and a time-varying study design, respectively, to compare major adverse cardiovascular events (MACEs) between patients receiving PD and HD. We also included 109 256 dialysis patients to compare the all-cause mortality among different RRT modalities.ResultsFor MACE, the hazard ratio (HR) for PD patients compared to HD patients was 0.95 [95% confidence interval (CI) 0.89–1.02] in the propensity score study design and 1.06 (95% CI 1.01–1.12) in the time-varying study design. For all-cause mortality, the HR for PD patients compared to HD patients was 1.09 (95% CI 1.05–1.13) in the propensity score study design and 1.13 (95% CI 1.09–1.17) in the time-varying study design. The HR for death was higher at a level of statistical significance for females (1.21, 95% CI 1.15–1.28), patients ≥65 years old (1.30, 95% CI 1.24–1.36) and diabetes mellitus (DM; 1.28, 95% CI 1.22–1.34).ConclusionsThe HR for MACE is significantly higher among PD patients in time-varying design analysis. In addition, all-cause mortality was higher in PD patients compared to patients with HD, especially in those who were aged ≥65 years, female or DM.
      PubDate: Sat, 12 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa282
      Issue No: Vol. 36, No. 5 (2020)
       
  • Cardiovascular risk of nonsteroidal anti-inflammatory drugs in dialysis
           patients: a nationwide population-based study
    • Authors: Jo H; Kim D, Park S, et al.
      Pages: 909 - 917
      Abstract: BackgroundGiven the cardiovascular risk of nonsteroidal anti-inflammatory drugs (NSAIDs), it is essential to identify the relationship between NSAIDs and cardiovascular outcomes in dialysis patients who have elevated cardiovascular risk.MethodsA case-crossover study was conducted to assess the association of NSAIDs with major adverse cardiac and cerebrovascular events (MACCEs) and mortality using the Korean Health Insurance dataset. The case period was defined as 1–30 days prior to the event date and the control periods were defined as 61–90 days and 91–120 days prior to the event date.ResultsThere were 3433 and 8524 incident dialysis patients who experienced MACCEs and mortality, respectively, after exposure to NSAIDs within 120 days before each event. NSAIDs significantly increased the risk of MACCEs {adjusted odds ratio [aOR] 1.37 [95% confidence interval (CI) 1.26–1.50]} and mortality [aOR 1.29 (95% CI 1.22–1.36)]. Nonselective NSAIDs, but not selective cyclooxygenase-2 inhibitors, significantly increased the risk of MACCEs and mortality. However, the MACCE and mortality risk did not increase in a dose-dependent manner in the analysis according to the cumulative defined daily dosage of NSAIDs. The incidence of MACCEs in the case period tended to be more common in patients who had recent exposure to NSAIDs than in patients who did not have recent exposure to NSAIDs.ConclusionsClinicians should be particularly cautious when prescribing NSAIDs to dialysis patients considering the associations of NSAIDs with cardiovascular outcomes and mortality, which might occur independent of the dose and duration of exposure.
      PubDate: Tue, 14 Jan 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfz276
      Issue No: Vol. 36, No. 5 (2020)
       
  • Dynamic prediction models for graft failure in paediatric kidney
           transplantation
    • Authors: Kaboré R; Ferrer L, Couchoud C, et al.
      Pages: 927 - 935
      Abstract: BackgroundSeveral models have been proposed to predict kidney graft failure in adult recipients but none in younger recipients. Our objective was to propose a dynamic prediction model for graft failure in young kidney transplant recipients.MethodsWe included 793 kidney transplant recipients waitlisted before the age of 18 years who received a first kidney transplantation before the age of 21 years in France in 2002–13 and survived >90 days with a functioning graft. We used a Cox model including baseline predictors only (sex, age at transplant, primary kidney disease, dialysis duration, donor type and age, human leucocyte antigen matching, cytomegalovirus serostatus, cold ischaemia time and delayed graft function) and two joint models also accounting for post-transplant estimated glomerular filtration rate (eGFR) trajectory. Predictive performances were evaluated using a cross-validated area under the curve (AUC) and R2 curves.ResultsWhen predicting the risk of graft failure from any time within the first 7 years after paediatric kidney transplantation, the predictions for the following 3 or 5 years were accurate and much better with the joint models than with the Cox model (AUC ranged from 0.83 to 0.91 for the joint models versus 0.56 to 0.64 for the Cox model).ConclusionAccounting for post-transplant eGFR trajectory strongly increased the accuracy of graft failure prediction in young kidney transplant recipients.
      PubDate: Tue, 29 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa180
      Issue No: Vol. 36, No. 5 (2020)
       
  • Triglyceride/HDL cholesterol ratio and premature all-cause mortality in
           renal transplant recipients
    • Authors: Anderson J; Bakker S, Tietge U.
      Pages: 936 - 938
      Abstract: The numbers of renal transplant recipients (RTR) are constantly increasing, already surpassing in several countries those of patients receiving haemodialysis treatment [1]. However, RTR still suffers an exceptionally high, but poorly understood, mortality burden [2]. This is partly attributable to a declining allograft function, and partly to dyslipidaemia, including decreased high-density lipoprotein cholesterol (HDL-C) and increased triglycerides (TGs) [3]. Frequently, HDL-C is low when TGs are high, a relationship particularly well reflected in the TG/HDL-C ratio [4]. As the only existing guideline that addresses lipid treatment in RTR, Kidney Disease: Improving Global Outcome (KDIGO), solely advises lifestyle changes to combat raised TG levels [5]. In the general population, the TG/HDL-C ratio constitutes a useful predictor of mortality, whereas interestingly in haemodialysis patients a protective effect is seen [6, 7]. Comparable data from RTR cohorts are not available. Therefore, we aimed to determine whether the TG/HDL-C ratio associates prospectively with mortality risk in RTR.
      PubDate: Sat, 12 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa321
      Issue No: Vol. 36, No. 5 (2020)
       
  • Urinary ezrin and moesin as novel markers for recovery from acute kidney
           injury
    • Authors: Kulvichit W; Wen X, Srisawat N, et al.
      Pages: 938 - 941
      Abstract: Acute kidney injury (AKI) is a common disorder associated with high morbidity and mortality among critically ill patients. Approximately 5% of all patients admitted to intensive care units around the world develop severe AKI requiring dialysis [1]. Currently there is no effective treatment to facilitate renal recovery in patients with AKI. The ability to forecast renal recovery is extremely valuable since it will provide physicians with an insight to optimize utilization of renal replacement therapy (RRT) and appropriate follow-up timing for these patients.
      PubDate: Sun, 13 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa328
      Issue No: Vol. 36, No. 5 (2020)
       
  • Need for uniform definitions in childhood nephrotic syndrome
    • Authors: Schijvens A; Sinha A, Bagga A, et al.
      Pages: 941 - 945
      Abstract: Nephrotic syndrome is one of the most common glomerular disorders in childhood [1, 2]. Although the majority of patients achieve complete remission after steroid treatment, >80% experience one or several relapses [3]. A significant proportion of patients progress to steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS), which is often an indication for additional immunosuppressive treatment [3, 4]. Patients who do not achieve remission after several weeks of steroid treatment are considered steroid resistant [5].
      PubDate: Sun, 27 Dec 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa338
      Issue No: Vol. 36, No. 5 (2020)
       
  • Errata
    • Authors: Boyer O; Dorval G, Servais A.
      Pages: 951 - 951
      Abstract: The genetics of steroid-resistant nephrotic syndrome in adults, Nephrol Dial Transplant 2020; gfz257. doi: 10.1093/ndt/gfz257
      PubDate: Thu, 17 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa185
      Issue No: Vol. 36, No. 5 (2020)
       
  • Erratum to: Managing Electrolyte Disorders: Order a Basic Urine Metabolic
           Profile
    • Authors: Sterns R.
      Pages: 952 - 952
      Abstract: Managing electrolyte disorders: order a basic urine metabolic panel, Nephrol Dial Transplant 2020; gfaa149. doi: 10.1093/ndt/gfaa149
      PubDate: Wed, 07 Oct 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa248
      Issue No: Vol. 36, No. 5 (2020)
       
  • Erratum to: Novel oral anticoagulants in patients with chronic kidney
           disease and atrial fibrillation
    • Authors: Stamellou E; Floege J.
      Pages: 952 - 952
      Abstract: Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation, Nephrol Dial Transplant (2018) 33: 1683–1689; doi: 10.1093/ndt/gfx322
      PubDate: Tue, 01 Sep 2020 00:00:00 GMT
      DOI: 10.1093/ndt/gfaa190
      Issue No: Vol. 36, No. 5 (2020)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.92.96.236
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-